Author/Authors :
rezapour, atefeh mashhad university of medical sciences - school of pharmacy - department of clinical pharmacy, Mashhad, Iran , moradian, maryam mashhad university of medical sciences - razavi hospital - department of research and education, Mashhad, Iran , nazemi, saeed mashhad university of medical sciences - razavi hospital - department of research and education, Mashhad, Iran , moallem, adel mashhad university of medical sciences - school of pharmacy - department of pharmacodynamics and toxicology, Mashhad, Iran , moallem, adel k , moallem, adel university of al zahra - faculty of pharmacy - department of pharmacology and toxicology, iran , issazadeh, sobhan mashhad university of medical sciences - razavi hospital - department of research and education, Mashhad, Iran , elyasi, sepideh mashhad university of medical sciences - razavi hospital - department of research and education, mashhad, iran , afshar, mohammad birjand university of medical sciences - department of anatomy, Birjand, Iran , afshar, mohammad birjand university of medical sciences - birjand cardiovascular disease research center - department of cardiology, Birjand, iran , baghshani, zahra mashhad university of medical sciences - school of pharmacy - department of clinical pharmacy, Mashhad, Iran , zaerzadeh, azadeh mashhad university of medical sciences - school of pharmacy - department of clinical pharmacy, Mashhad, Iran , z, a m , mohammadpour, amir hooshang mashhad university of medical sciences - pharmaceutical research center, Mashhad, iran , mohammadpour, amir hooshang mashhad university of medical sciences - school of pharmacy - department of pharmacodinamy, Mashhad, Iran
Abstract :
Background: Coronary artery calcification (CAC) is utilized as an important tool for the global risk assessment of cardiovascular events in individuals with intermediate risk. Biglycan (BGN) is a small leucine‑rich proteoglycan that induces the calcification of arterial smooth muscle cell. This study aimed to evaluate the correlation between BGN serum concentration and CAC in human for the first time. Patients and Methods: Eighty‑four patients with coronary artery disease (CAD) were included in the study. A questionnaire consisting of demographic data and traditional cardiovascular risk factors was completed for all patients. patients did not complete the questionnaire, it was completed by the pharmacy student. CAC score and BGN serum concentrations were determined using computed tomography angiography and enzyme‑linked immunosorbent assay method, respectively. Results: There was no significant correlation between BGN serum concentration and total CAC score and also CAC of different branches of coronary artery (P 0.05). Conclusion: On the basis of our results, BGN serum concentration is not a suitable biomarker of CAD. Studies with a higher sample size are necessary for its confirmation.
Keywords :
Biglycan , biomarker , coronary artery calcification , glycosaminoglycan , proteoglycans , tumor necrosis factor‑β
